Adverse Events of Tracheobronchial Stents: A MAUDE Database Study With Focus on Metallic Stents Authors: Janvi J Shukla, Nicholas S Hamilton, Sraavya Anne, Kenneth Yan, Rachel Kaye Published: 2026 ABSTRACT ABSTRACTObjectivesTracheobronchial stents treat conditions that reduce airflow such as malignancy, tracheomalacia, and stenosis, but may fail and cause complications. This study aims to use the US Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database to understand adverse events related to tracheobronchial stent use to reduce future complications.MethodsThe MAUDE database was searched for “Prosthesis, Tracheal, Expandable,” “Prosthesis, Tracheal, Expandable, Polymeric,” and “Prosthesis, Tracheal, Preformed/Molded” from January 2014 to December 2023. Reports were analyzed and complications were categorized.ResultsWe identified 525 reports. 405 (77.1%) reports listed indications including airway stenosis (n = 312, 51.0%), malignancy‐related airway stricture (n = 258, 42.2%), tracheoesophageal fistula (n = 26, 4.2%), and tracheobronchomalacia (n = 16, 2.6%). A total of 768 different adverse events were cataloged. The most common device‐related complication was stent deployment failure (N = 236, 30.7%). 94 patient injuries occurred; the most common patient injury was airway occlusion/collapse (n = 26, 28.6%), followed by airway bleeding/exsanguination (N = 12, 13.6%), and intubation/ICU care (N = 11, 12.5%). Six cases led to death (0.7%). Stents placed due to tracheobronchomalacia had more cases of airway occlusion/collapse, pneumonia, and intubation/ICU care than all other indications (all p < 0.05).ConclusionMost adverse events were related to technical failure while severe complications such as airway obstruction were few, and mortality was rare. These risks are important to note when utilizing tracheobronchial stents.Level of Evidence4.Keywords: malignancy, stenosis, tracheobronchial stent, tracheobronchomalacia, tracheoesophageal fistula Introduction Tracheobronchial stents are medical devices constructed from metal, mesh, or silicone rubber that are used to alleviate airway obstruction, occlude tracheoesophageal fistulas, and treat tracheomalacia, stenosis, and malignancy [1]. In 1965, Montgomery described the use of a silicone‐based T‐tube in the airway to treat tracheal stenosis. This was later modified by Dumon in 1990 through the introduction of the first endoluminal airway stent [2]. Today, endoluminal airway stents are widely utilized in treating central airway obstruction, and the use of metal stents in particular remains high [3]. Tracheobronchial stents come with a range of potential complications, which can vary by stent type, including stent migration, development of granulation tissue, stent fracture, placement issues, poor patient tolerance, and infection. These complications may vary by stent type or material, as well as by individual patient factors such as underlying conditions and airway anatomy. Metal stents maintain certain advantages over alternate stent materials, such as ease of placement and reduced risk of migration [4]. However, metal stents are also associated with unique complications and difficulties, especially during their removal and are not typically used in patients with benign airway stenosis [5, 6]. Specifically, metal stents have the potential for excessive granulation tissue formation, which can impact long‐term airway patency and patient outcomes. Severe complications, such as airway rupture or the development of fistulas, have also been documented [4, 7, 8, 9]. Beyond metallic stents, silicone stents are widely used and are characterized by their ease of removal, low cost, and protection against tumor ingrowth, though they require rigid bronchoscopy for placement under general anesthesia and carry higher rates of migration and mucus inspissation [2, 3, 10]. Hybrid stents, composed of a metal framework coated with silicone or polyurethane, as well as emerging biodegradable polymeric stents made from materials such as polydioxanone and poly‐L‐lactic acid, represent newer designs that aim to combine the structural advantages of metallic stents with the removability and biocompatibility of silicone, though most biodegradable stent data remain preclinical [11, 12]. These factors should be considered when selecting stent materials for the treatment of airway obstruction. It is crucial for physicians and patients to understand the risks of tracheobronchial stent usage to perform the cost–benefit analysis for patients with specific indications. To date, most studies evaluating tracheobronchial stent complications have been limited to single‐center retrospective series with small cohorts. For example, Zakaluzny et al. reported complications in 28 patients, Jeong et al. in 52 patients, and Breitenbücher et al. in 62 patients, limiting the ability to detect differences in complication rates across stent indications [5, 7, 13]. In addition, most papers focus on postoperative complications, while excluding intraoperative complications [3, 7, 14, 15]. To this end, we sought to investigate these complications using the Manufacturer and User Facility Device Experience (MAUDE) database. The MAUDE database is a publicly accessible database maintained by the Food and Drug Administration (FDA) that aggregates post market safety reports related to medical devices. It catalogs medical device reports describing adverse events which are collected through the FDA's Medical Device Reporting system by required and voluntary reporting by manufacturers, device user facilities, physicians and other consumers. MAUDE serves as a tool for monitoring real‐world device performance and safety [16]. While the MAUDE database has been increasingly utilized to characterize adverse events for other airway devices, no study to date has applied this approach to tracheobronchial stents [17]. Furthermore, existing clinical studies of tracheobronchial stent complications are predominantly single‐center retrospective series with limited sample sizes, and none have systematically compared adverse event profiles across different clinical indications. Here we sought to use the MAUDE database to characterize complications related to all stent types but found that the database mainly characterized metallic stents. This database offers a unique opportunity to address these gaps by providing a multi‐institutional, national‐level dataset that captures both device malfunctions and patient injuries, including intraoperative events that are often excluded from traditional clinical series. Due to the potential complications that may arise for patients from these stents, a more thorough understanding of the adverse events (AEs) related to tracheobronchial stents, particularly metal stents, is necessary. An improved understanding of these AEs is essential to identify areas where interventions are needed to minimize complications. Therefore, our study aims to examine AEs due to tracheobronchial stents. Furthermore, we aim to stratify these AEs based on clinical indication in order to gain more insight into how different procedural contexts can influence the risk of an AE. Identifying the most commonly reported complications and examining indication‐specific adverse event patterns may have direct clinical utility by informing patient counseling, guiding post‐procedural surveillance strategies, and optimizing procedural planning, particularly for higher‐risk indications such as tracheobronchomalacia. Methods The MAUDE database was queried for the 10‐year period from January 2014 to December 2023 for the product classes “Prosthesis, Tracheal, Expandable,” “Prosthesis, Tracheal, Expandable, Polymeric,” and “Prosthesis, Tracheal, Preformed/Molded.” The MAUDE database, maintained by the Food and Drug Administration (FDA), is used for reporting such AEs related to medical device usage. This database catalogs AEs and stores reports for 10 years at a time. Reports containing missing variables and duplicates were excluded. Data extracted from the reports included device malfunction type and patient outcome, which were then categorized into major or minor events based on perceived clinical severity and need for intervention. Major events were defined as: empyema, pneumonia, tracheostomy, hypoxia/dyspnea, heart failure/bradycardia, airway bleeding/exsanguination, airway fistula, airway occlusion/airway collapse, airway perforation, pneumothorax, intubation/ICU, loss of consciousness and/or death. All other complications were defined as minor events (failure to deploy, activation failure, stent break, deployment in incorrect location, migration after deployment, failure of delivery system catheter to be withdrawn, post‐procedure complication, pre‐procedure complication, unraveled stent retention structure, pre‐deployment complication, granulation). When a single report listed multiple AEs, each AE was individually collected, thus accounting for more AEs than total number of reports. Clinical indications were investigated where the Fisher's Exact test was used to compare complications across indications. As the majority of patients presented with multiple indications, individual patients could contribute to more than one indication‐specific subgroup analysis. Given the exploratory nature of this study, formal adjustment for multiple comparisons was not applied. Results Demographics An initial query of the MAUDE database from January 2014 through December 2023 identified 1389 reports. After excluding reports involving non‐endobronchial stents (n = 750), review articles (n = 87), duplicate reports (n = 15), incomplete reports (n = 6), and blank reports (n = 6), a total of 525 reports were included in the final analysis. A total of 525 reports related to tracheobronchial stent usage were identified between January 2014 and December 2023. Age, gender and race were not specified in any of the reports. Indication for use was reported in 405 (77.1%) of tracheobronchial stent reports as shown in Table 1. Multiple indications for use of a stent were noted in 327 reports, such that the total number of indications (n = 612) exceeds the number of AE reports. The most common indications were airway stenosis (n = 312, 51.0%) followed by malignancy‐related airway stricture (n = 258, 42.2%), tracheoesophageal fistula (n = 26, 4.2%), and tracheobronchomalacia (n = 16, 2.6%). Metal stents accounted for 98.5% of those in the database. TABLE 1Indications for tracheobronchial stent placement.IndicationNumber (%)Total n = 612Airway stenosis312 (51.0%)Malignancy‐related airway stricture258 (42.2%)Tracheoesophageal fistula26 (4.2%)Tracheobronchomalacia16 (2.6%) Note: Indications can be found in the left‐sided column. The number and percent of patients who had a specific indication can be found in the right‐sided column. Indications for tracheobronchial stent placement. Note: Indications can be found in the left‐sided column. The number and percent of patients who had a specific indication can be found in the right‐sided column. Adverse Events A total of 768 different AEs were cataloged from the 525 identified reports. Of the 768 different reported AEs, 91 (11.8%) were classified as major complications while 677 (88.2%) were classified as minor complications (Tables 2 and 3). The most common AE was stent deployment failure (n = 236, 30.7%), followed by stent activation failure (n = 105, 13.7%) and stent breakage (n = 94, 12.2%). A total of 94 patient injuries occurred in 70 (13.3%) reports (Figure 1). The most common patient injury was airway occlusion/collapse (n = 26, 28.6%), followed by airway bleeding/exsanguination (n = 12, 13.6%) and intubation/ICU care (n = 11, 12.5%). A total of six cases resulted in death (0.7% overall). Death events occurred due to bronchial and pericardium perforation (n = 1), bronchial and esophageal perforation (n = 1), pneumonia causing respiratory arrest (n = 1), spontaneous airway occlusion (n = 2), and unknown (n = 1). TABLE 2Major complications.Major complicationsNumberCategorical percentage (n = 91)Overall percentage (n = 768)Airway occlusion/airway collapse2628.6%3.4%Airway bleeding/exsanguination1213.2%1.6%Intubation/ICU1112.1%1.4%Pneumonia99.9%1.2%Empyema88.8%1.0%Hypoxia/dyspnea88.8%1.0%Death66.6%0.8%Loss of consciousness33.3%0.4%Airway perforation22.2%0.3%Pneumothorax22.2%0.3%Bradycardia22.2%0.3%Heart failure11.1%0.1%Airway fistula11.1%0.1% Note: Major complications are listed with the corresponding number of patients affected, categorical percentage, and overall percentage. The categorical percentage is calculated from the total number of major complications. The overall percentage is calculated from the number of total complications. Major complications. Note: Major complications are listed with the corresponding number of patients affected, categorical percentage, and overall percentage. The categorical percentage is calculated from the total number of major complications. The overall percentage is calculated from the number of total complications. TABLE 3Minor complications.Minor complicationsNumberCategorical percentage (n = 677)Overall percentage (n = 768)Failure to deploy23634.9%30.7%Activation failure10515.5%13.7%Stent break9413.9%12.2%Deployment in incorrect location7210.6%9.4%Migration456.6%5.9%Failure of delivery system catheter to be withdrawn355.2%4.6%Post‐procedure complication345.0%4.4%Pre‐procedure complication263.8%3.4%Unraveled stent retention suture162.4%2.1%Pre‐deployment complication111.6%1.4%Granulation30.4%0.4% Note: Minor complications are listed with the corresponding number of patients affected, categorical percentage, and overall percentage. The categorical percentage is calculated from the total number of minor complications. The overall percentage is calculated from the number of total complications. Minor complications. Note: Minor complications are listed with the corresponding number of patients affected, categorical percentage, and overall percentage. The categorical percentage is calculated from the total number of minor complications. The overall percentage is calculated from the number of total complications. Patient injuries. This pie chart illustrates the distribution of patient injuries. Each color corresponds to a specific patient injury, as detailed in the key (e.g., airway occlusion/collapse—dark blue, airway bleeding/exsanguination—light blue, intubation/ICU—dark orange). Each patient injury listed in the key includes the number of patients with that injury (n) and the percent of total injuries. Stents placed due to tracheobronchomalacia had more patient injuries compared to other indications (Figure 2). Specifically, they had a higher rate of airway occlusion/collapse (n = 6, 37.5%) compared to malignancy‐related airway stricture (n = 5, 1.94%, p < 0.005), airway stenosis (n = 17, 5.45%, p < 0.005), and tracheoesophageal fistula (n = 0, 0.0%, p < 0.005). They also had a higher rate of pneumonia (n = 4, 25.0%) compared to malignancy‐related airway stricture (n = 4, 1.55%, p < 0.0005), airway stenosis (n = 8, 2.56%, p < 0.002), and tracheoesophageal fistula (n = 0, 0.0%, p < 0.05). Finally, these patients also had a higher rate of intubation/ICU care (n = 4, 25.0%) compared to malignancy‐related airway stricture (n = 4, 1.55%, p < 0.0005), airway stenosis (n = 7, 2.24%, p < 0.002), and tracheoesophageal fistula (n = 0, 0.0%, p < 0.05). Complications of tracheobronchial stents by indication. This bar chart shows the complication percentages for the four most common injuries, stratified by procedure indication. Bars represent complication rates for tracheobronchomalacia (red), malignancy‐related airway stricture (blue), airway stenosis (green), and tracheoesophageal fistula (yellow). Asterisks indicate statistically significant differences between indications (p < 0.005). Regarding intervention following AEs, stents were removed and replaced with a new device in 358 (68.2%) reports. Stents were removed and not replaced in 102 reports (19.2%). Stents remained implanted in the deployment location in 32 (6.2%) reports and were repositioned in 12 (2.3%) reports (Table 4). The only statistically significant difference in the management of stent failures based on AE was that stent breakage resulted more frequently in removal (n = 24, 25.5%) compared to stent deployment failure (n = 37, 15.7%, p < 0.02). TABLE 4Stent outcomes.Stent outcomeNumber (%)Total n = 525Stent removed without replacement102 (19.2%)Stent removed and replaced358 (68.2%)Stent remained32 (6.1%)Stent repositioned12 (2.3%)Not stated21 (4.0%) Note: Outcomes can be found in the left‐sided column. The number and percent of patients who had a specific outcome can be found in the right‐sided column. Stent outcomes. Note: Outcomes can be found in the left‐sided column. The number and percent of patients who had a specific outcome can be found in the right‐sided column. Discussion The use of tracheobronchial stents can result in complications such as airway perforation, tissue granulation, and even death. A previous study on the Ultraflex tracheobronchial stent, a metal stent, found complications in 14 out of 62 (22%) cases, including mucus plugging, stenosing granulation tissue, tumor ingrowth, and stent migration [13]. We interrogated the MAUDE database to analyze complications related to metallic tracheobronchial stents. To this end, we report the complications of 525 AE reports with analysis of the risks of specific indications to better understand the complications associated with the use of tracheobronchial stents. Importantly, the rates reported in this study represent proportions of adverse events among reported cases in the MAUDE database, not true incidence rates, as the database does not capture the total number of stent placements performed. Additionally, because MAUDE is a passive surveillance system, complications may be differentially reported, with acute device malfunctions more likely to be captured than delayed clinical complications; therefore, comparisons with rates from clinical cohort studies should be interpreted cautiously. In our cohort, we found that the most common patient injuries associated with stents were airway occlusion, airway bleeding, intubation/ICU needs, and pneumonia. Additionally, we found that tracheobronchomalacia was associated with higher risks of these complications. Tracheobronchomalacia is the loss of structural integrity of airway cartilaginous structures leading to collapse during the intraluminal pressure changes of respiration [18]. Stents placed for tracheobronchomalacia in our study consisted of only 2.6% (n = 16) of complications, however, they were associated with significantly higher rates of complications compared to other indications. The incidence of airway occlusion/collapse, pneumonia, and intubation/ICU care was markedly higher in cases of tracheobronchomalacia than in cases of malignancy‐related airway stricture, airway stenosis, and tracheoesophageal fistula. This suggests that tracheobronchomalacia may be a high‐risk indication for tracheobronchial stent placement. While the small sample size (n = 16) warrants cautious interpretation, these findings suggest that tracheobronchomalacia may represent a higher‐risk indication for tracheobronchial stent placement. The lack of structural integrity in the airway may cause stents to shift position, leading to occlusion, pneumonia, and need for intubation or ICU care. Our findings correlate well with established literature as Hramiec et al. reported a 46% complication rate in 24 patients among two studies where tracheobronchial stents were used to treat tracheobronchomalacia [19]. They propose that the increased flexibility of the trachea in tracheobronchomalacia subjects the stents to cyclical stress with respiration more than other indications, leading to stent wear and degradation [19]. While the data in this study predates contemporary stent design, the physiologic principle they propose remains applicable. In addition, Zakaluzny et al. reports an 8% (1/13) complication rate for stents placed for malignant diseases, compared to a 53% (8/15) complication rate for benign diseases, including two cases of tracheobronchomalacia [7]. In a paper by Vander et al., 50% of patients with tracheal compression due to mediastinal masses had flow volume loops consistent with fixed obstruction [20]. This contrasts with the obstruction pattern in tracheomalacia where collapse primarily occurs in the expiratory portion of respiration [21]. Therefore, the higher proportion of stent‐related complications in tracheomalacia may be secondary to dynamic collapse, which is seen less in malignant disease. Given the limited number of tracheobronchomalacia cases in this dataset, a meta‐analysis aggregating complication data across multiple studies and stent types would be a valuable next step to validate these findings and better characterize the risk profile of placing stents in this population. Airway occlusion or collapse after stenting can be a result of a granulation reaction to the stent, or a failure of the stent to counteract the initial cause of stenosis (e.g., tumor growth) [22]. In this study, the most common major complication/patient injury was airway occlusion/collapse (n = 26, 28.6%), which correlates with current literature. Ost et al. reports the following incidence rates for airway occlusion and collapse related to airway stents: tumor overgrowth (12.8%), granulation (19.5%), and mucus impaction (24.6%) [15]. Our findings support current guidelines which suggest performing postoperative surveillance bronchoscopies to identify potential issues before they result in patient morbidity [23]. Airway bleeding/exsanguination can occur when the stent is placed near a blood vessel or if there is a puncture of the airway. Airway bleeding is also possible when a stent is placed to counteract external airway compression from a vessel, as the pressure gradient between structures can result in pressure necrosis and erosion [24]. We found a bleeding complication rate of 13.6% which is similar to that currently reported in the literature of 20.0% [24]. Aside from exsanguination due to vessel damage, less severe airway bleeding has been found to lead to hemoptysis, which occurs in 8.7% of stenting procedures according to the literature [15]. Physicians can address these issues by considering the vascular architecture surrounding a patient's airway stenosis when deciding to place a stent. Contracting pneumonia is a known complication of tracheobronchial stent placement. A possible mechanism for this is the disruption of mucociliary clearance by the stent, thus decreasing the natural defense of the pulmonary system. We found the incidence of pneumonia as a result of airway stent placement to be 10.2% which is lower than that currently reported in the literature at 28.7% [15]. This may be due to a reporting bias as the MAUDE database primarily reports stent malfunction and is likely underreporting the development of pneumonia in those with a mechanically functioning stent. Airway granulation is a result of the natural healing process of tissue and is a response to irritation/inflammation to the tissue adjacent to the stent [25]. Similar to our rate of stent‐associated pneumonia, our rate of granulation (n = 3, 0.4%) was substantially lower than what is currently touted in the literature at approximately 19.5% [15]. This is likely due to a reporting bias similar to the prevalence of pneumonia; patients who develop granulation but have a functioning stent are not likely reported within the data set. As a result, there would be fewer reports of granulation in the MAUDE database. The MAUDE database has many benefits to its use, but it also has intrinsic limitations. The database consists of mandatory and volunteer retrospective reporting of complications, which makes underreporting likely. Additionally, several forms of reporting bias are inherent to this structure, including social desirability bias, recall bias, and reference bias, all of which may influence which events are reported and how they are characterized. Cases where a complication occurred, but the stent was mechanically intact and therefore did not technically malfunction as well as minor complications such as dysphonia and odynophagia are at particular risk of underreporting. Furthermore, details of the procedure such as location of initial stent placement are not consistently captured, despite the likelihood that stent location influences outcomes. It is therefore difficult to determine risk factors for certain complications. Adverse events were classified as major or minor by the authors based on perceived clinical severity, as MAUDE lacks a standardized severity grading system. This subjective approach may not fully capture the clinical significance of individual events, which can vary depending on the patient and circumstance. Additionally, the MAUDE database frequently lacks demographic information including age, sex, and race, limiting assessment of these patient‐level risk factors. The database also only reports events with complications, and not the total number of events. This means it is impossible to calculate the prevalence or incidence of complications. Only relative comparisons between categories can be made. Furthermore, multiple pairwise comparisons were performed without formal correction for multiple testing, increasing the risk of type I error. Given the exploratory nature of this analysis, correction methods were not applied to avoid excessive type II error. In addition, as 327 of 405 patients (80.7%) presented with multiple indications, Fisher's Exact comparisons across indication subgroups were performed on non‐independent samples. Results should be interpreted as descriptive characterizations of complication profiles within each indication rather than mutually exclusive group comparisons. Accordingly, significant findings should be considered hypothesis‐generating rather than confirmatory and require validation in prospective studies. Another important limitation is the database's inability to differentiate between uncovered, partially covered and fully covered metallic stents. Uncovered stents were used more frequently earlier in the study period but are less commonly utilized in contemporary practice, which may skew complication patterns over time and limit the applicability of findings to current practice [11]. An important limitation of this study is the inability of the MAUDE database to distinguish between uncovered (bare), partially covered, and fully covered metallic stents. This distinction is clinically significant, as stent covering design substantially influences complication profiles. Uncovered metallic stents are associated with higher rates of granulation tissue hyperplasia due to direct contact between the metal lattice and airway mucosa, and their removal is notoriously difficult due to neoepithelization and tissue ingrowth through the stent framework [26, 27]. In contrast, fully covered stents demonstrate lower granulation tissue formation but higher rates of migration [28, 29]. The 2005 FDA public health notification warned against the use of uncovered metallic stents in benign airway disease, and contemporary practice has shifted toward fully covered designs [11, 30]. Because our study period spans 2014–2023, the dataset likely includes a heterogeneous mix of stent subtypes, with uncovered stents more prevalent in earlier reports. This heterogeneity may confound the observed complication rates; for example, the low rate of granulation tissue in our cohort (0.4%) compared to the literature (~19.5%) may partly reflect the increasing predominance of covered stents over the study period, in addition to reporting bias [15]. Clinicians should interpret these findings with caution, as complication rates may differ substantially depending on the specific stent design used. Furthermore, silicone and metallic stents exhibit distinct complication profiles, with silicone stents more frequently associated with migration and metallic stents with tissue ingrowth and more challenging removal. Prior studies and a recent meta‐analysis have also demonstrated variation in complication patterns according to both stent type and indication, highlighting that findings from this predominantly metallic stent cohort may not be generalizable to all tracheobronchial stents [12, 31]. Conclusion Complications arising from tracheobronchial stents range from minor technical events such as deployment failure to severe patient injuries including airway obstruction, and mortality was rare (0.7%). The high relative rate of stent deployment failure (30.7%) underscores the importance of preoperative CT‐based airway assessment for stent sizing and the availability of backup stent options during the procedure. Tracheobronchomalacia was associated with significantly higher rates of airway occlusion/collapse, pneumonia, and need for intubation/ICU care compared to all other indications, suggesting that these patients may warrant more intensive perioperative monitoring and a lower threshold for postoperative surveillance bronchoscopy. Airway occlusion/collapse as the most common patient injury (28.6%) reinforces guideline recommendations for surveillance bronchoscopy to detect granulation tissue, mucus plugging, or tumor overgrowth before critical airway compromise occurs [23]. Surgeons should weigh these indication‐specific risks alongside stent‐specific complication profiles when selecting a tracheobronchial stent for a given patient. Funding The authors have nothing to report. Disclosure The authors did not use any AI‐assisted tools in the preparation of this manuscript. Conflicts of Interest The authors declare no conflicts of interest. Shukla J. J., Hamilton N. S., Anne S., Yan K., and Kaye R., “Adverse Events of Tracheobronchial Stents: A MAUDE Database Study With Focus on Metallic Stents,” Laryngoscope Investigative Otolaryngology 11, no. 4 (2026): e70523, 10.1002/lio2.70523. Poster Presentation at The Fall Voice Conference 2025, Charlotte, NC, September 2025. Data Availability Statement The data that support the findings of this study are openly available in MAUDE Database at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm. References Associated Data Data Availability Statement The data that support the findings of this study are openly available in MAUDE Database at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm.